When HS Develops Tunnels Beneath the Skin
Sinus tracts in HS are not a separate disease — they are what happens when repeated inflammation is never fully resolved and the internal drivers are never addressed. Each unresolved lesion leaves behind structural changes. Over months and years, these changes connect into the tunnelling pattern that defines this stage of HS.
Why the Body Forms Tunnels in HS
AyurvedaSrotorodha — Channel ObstructionSinus tract formation is not a random complication. It is the predictable outcome of repeated, incompletely resolved inflammatory cycles in the same tissue locations. Understanding why tunnels form is inseparable from understanding what must change to stop them.
The Structural Consequence of Repeated Cycles
Each time an HS lesion forms and resolves — even partially — it leaves behind microstructural changes. The dermis and subcutaneous tissue in the affected area become progressively less ordered. Collagen architecture is disrupted. Minor fibrotic changes accumulate. Lymphatic drainage pathways in the region become compromised.
After multiple lesion cycles in the same area, these accumulated changes create pathways of least resistance within the tissue — channels along which inflammatory material can travel. What begins as a single abscess begins to communicate with adjacent inflamed follicular units through these weakened tissue planes. This is sinus tract formation: not a new disease process, but the structural expression of a prolonged one.
The key clinical implication is that sinus tracts are not primarily a surgical problem. They are a record of years of unresolved internal inflammation — and that inflammation is still active while the tract exists.
Why Discharge Continues
Patients with tunnel-forming HS often experience continuous or near-continuous discharge from one or more sites. This is clinically significant beyond the obvious practical burden it creates. Continuous discharge indicates that the sinus tract is connected to an ongoing inflammatory source — a collection of active tissue that is still generating inflammatory material faster than the body can clear it.
Discharge that stops and restarts, or that reduces with antibiotics but returns when they are stopped, follows the same logic. The antibiotics temporarily reduce bacterial involvement in the active inflammation — but the underlying inflammatory driver (gut dysfunction, hormonal imbalance, immune dysregulation) remains unchanged. When the antibiotic course ends, the internal environment continues generating the same inflammatory cascade.
This is why discharge is not simply a surface problem to be dressed or managed — it is a signal that internal correction has not occurred.
The Follicular Origin
Sinus tracts originate in damaged hair follicles. Repeated blockage and rupture destroys the follicular wall, creating an opening into the surrounding dermis. The body attempts to wall off this inflammatory focus — the fibrotic capsule that forms becomes the structural basis of the early sinus tract.
Subcutaneous Extension
As inflammation persists, the tract extends into the subcutaneous fat layer — where tissue planes offer relatively little structural resistance. The tract follows these planes, connecting to adjacent follicular units or abscess collections. This is why a single visible opening on the skin surface can connect to a much larger network of inflamed tissue beneath.
Epithelialisation — The Persistent Wall
Over time, the lining of the sinus tract becomes epithelialised — the body lines it with epithelial cells in an attempt to contain the ongoing inflammation. This epithelial lining prevents spontaneous closure of the tract, which is why sinus tracts do not simply heal on their own and why the inflammatory process within them can persist for years.
How Tunnel-Forming HS Develops Step by Step
The transition from nodular HS to tunnel-forming HS is not sudden. It follows a recognisable progression — one that reflects the gradual structural consequences of persistent internal inflammation.
Recurrent Nodules in Fixed Locations
The initial stage involves repeated inflammation in the same tissue areas — the same follicular units or clusters of follicles, in the same body regions. Each cycle follows a similar pattern: a nodule appears, may partially resolve, and then recurs. The internal inflammatory driver — gut-derived toxin load, hormonal excess, immune dysregulation — continues to stimulate new lesion formation between resolution events.
Tissue Damage Accumulates Between Cycles
Each lesion cycle deposits microstructural damage. The dermis in repeatedly affected areas becomes progressively disorganised. Collagen is replaced by fibrotic tissue that does not have the same structural integrity. Capillary and lymphatic networks in the affected zone are disrupted. The tissue becomes structurally compromised — increasingly vulnerable to the next inflammatory cycle, which requires less stimulus to initiate and resolves less completely than the one before.
Early Sinus Formation — Connection Between Sites
As tissue planes weaken, inflammatory collections from adjacent lesion sites begin to communicate. A subcutaneous channel forms between them — not yet fully epithelialised, but functionally connecting two areas of active inflammation. The patient may notice that pressing on one lesion affects another, or that a draining site is not directly over the palpable inflamed area. These are early signals that sinus tract architecture is forming.
Epithelialisation — Tracts Become Permanent Structures
Once the body lines the internal channel with epithelium, the sinus tract becomes a fixed anatomical structure. It no longer resolves spontaneously. The tract maintains a persistent connection between its endpoints — often between multiple follicular origins and one or more external drainage points. This epithelial lining is also the reason why systemic treatment alone cannot physically remove established sinus tracts — the structural change is permanent unless surgically excised.
Network Expansion — Multiple Tracts, Continuous Activity
Without internal correction, the process continues. New follicular units in the affected region are recruited into the inflammatory cycle. Additional sinus tracts form and connect. The network expands — increasingly difficult to map, increasingly resistant to local intervention. At this stage, the systemic inflammatory burden from the ongoing HS is significant enough to affect metabolic function, hormonal balance, and immune regulation — creating a self-sustaining cycle that goes beyond the original triggering factors.
Why Tunnel-Forming HS Keeps Coming Back
Many patients with tunnel-forming HS have been through surgery — sometimes multiple times. The pattern that follows is almost always the same: temporary relief, then new lesion formation, then progressive recurrence. This is not a failure of the surgery. It is the predictable outcome of treating a structural consequence without addressing the systemic cause.
Without correction of the internal drivers that created the sinus tracts, new lesions form in adjacent areas or at the surgical margins. The surgery removes existing structure — it cannot alter the internal environment that generates new structure.
Most patients with tunnel-forming HS have had HS for several years before sinus tracts develop — often during a period of symptomatic management without root cause correction. The tunnelling reflects accumulated, unaddressed internal inflammation.
By the time tunnelling is established, the condition has typically progressed beyond a single driver. Gut dysfunction, immune dysregulation, hormonal imbalance, and metabolic burden are usually all present — compounding each other in ways that make single-system treatment insufficient.
"Surgery addresses the structural expression of the disease. The internal inflammatory process that created the structure continues unless it is directly corrected. This is why recurrence after surgery is the rule, not the exception, in tunnel-forming HS without systemic treatment."
How Tunnel-Forming HS Presents at Different Stages
The degree of tunnelling and its impact on daily life changes significantly from early to advanced presentation. Understanding where a patient currently sits in this progression determines the sequencing and intensity of the treatment approach.
Early Sinus Formation
One or two sinus tracts connecting adjacent lesion sites. Intermittent drainage. Underlying nodules still the dominant feature. At this stage, aggressive internal correction alongside careful local support can significantly alter the trajectory — preventing the network expansion that defines later stages.
Established Network
Multiple interconnected sinus tracts, frequent discharge, significant fibrosis in affected areas. New lesions continue to form. This is where many patients present after a period of repeated antibiotic courses and one or more surgical procedures. The internal drivers are well-established and multiple systems are typically involved. Treatment at this stage requires patience and systematic phased approach.
Advanced Diffuse Disease
Extensive tunnelling across large anatomical areas. Continuous drainage, significant scarring, compromised mobility or function in some cases. Multiple systems deeply involved. At this stage, the goal is systemic correction first — reducing the active inflammatory burden — before any consideration of structural intervention. The disease has developed sufficient internal momentum that sustained systemic treatment is required before local measures are relevant.
What Treatment at This Stage Actually Requires
Tunnel-forming HS is the most structurally advanced presentation in the HS spectrum. Treatment must reflect that complexity. The EPOH Protocol approaches this stage with a clear sequence — addressing the systemic inflammatory environment before targeting the structural consequences, because structural healing cannot proceed while the internal inflammatory process remains active.
The critical foundation
At this stage, the systemic inflammatory burden from ongoing HS is significant. The gut-derived toxin load, circulating immune mediators, and metabolic inflammatory signals are all at elevated levels — and they are actively sustaining the sinus tract activity. The first priority is reducing this systemic load to a point where the body's own healing mechanisms can begin to operate.
Without this phase, all subsequent phases produce limited results. The internal environment is too inflammatory for tissue repair to occur meaningfully, and the hormonal and immune corrections of later phases cannot consolidate in an environment of ongoing systemic inflammation.
Addressing what created the tunnels
In tunnel-forming HS, the root cause is rarely a single factor. By this stage, gut dysfunction, hormonal imbalance, immune dysregulation, and metabolic burden are usually all present to varying degrees. Each patient's driver profile is different — the relative contribution of each factor, and the sequence in which they are addressed, is determined through evaluation rather than through a fixed protocol.
This phase may run concurrently with Phase 01 in different formulation channels — addressing gut function and inflammatory load simultaneously while beginning the hormonal and immune correction work.
Supporting the healing environment locally
As the systemic inflammatory environment begins to stabilise, local support for the sinus tract tissue becomes relevant. This involves reducing the active inflammatory process within the tracts, supporting lymphatic drainage in the affected region, and creating an internal microenvironment that is less hospitable to ongoing inflammation and bacterial colonisation.
External topical support is applied alongside internal formulations at this stage — not as a standalone intervention, but as a complement to the systemic correction occurring internally.
Rebuilding damaged tissue
Once the active inflammatory process within the sinus tract network is significantly reduced, the focus shifts to tissue repair. Years of repeated inflammation have disrupted the structural architecture of the affected areas — fibrosis, impaired circulation, and reduced tissue integrity are all present. This phase supports the remodelling of fibrotic tissue, improved microvascular supply to healing areas, and gradual restoration of tissue function.
This is a slower phase, and progress is measured in months rather than weeks. Tissue that has been compromised over years cannot regenerate rapidly — but the trajectory changes when the internal inflammatory environment has been corrected.
Maintaining the corrected state
The final phase focuses on sustaining the systemic correction that has been achieved — building regulatory resilience in the gut, immune, and hormonal systems so that normal life stress, dietary variation, and hormonal fluctuation do not restart the inflammatory cycle. In tunnel-forming HS, this phase is particularly important because the structural vulnerability that enabled tunnel formation does not disappear — it must be managed through maintained systemic correction.
When Surgery Is and Is Not Relevant
Surgery is sometimes necessary in tunnel-forming HS — particularly when epithelialised tracts have created stable, non-inflamed structures that are causing mechanical problems, or when a specific anatomical area requires debridement to allow healing to proceed.
However, surgery in the context of active internal inflammation produces predictable results: temporary relief, followed by recurrence in adjacent areas or at surgical margins. New follicular units continue to receive the same internal inflammatory signal and progress through the same disease cycle. The surgical site heals — then the process begins again nearby.
Surgery is most effective when it addresses a specific structural problem after the internal environment has been meaningfully corrected — not as the primary response to active, systemic HS. When internal correction precedes surgery, the post-surgical environment is significantly less hospitable to recurrence.
Herbal Formulations for Tunnel-Forming HS
The formulation framework for tunnel-forming HS is more intensive than earlier stages, reflecting the depth and duration of systemic involvement. Each formulation targets a specific layer of the condition — from systemic inflammatory load to local tissue repair — and is composed individually based on the patient's current state and driver profile.
Deep Detox and Inflammatory Load Formula
Designed to systematically reduce the accumulated inflammatory toxin load that sustains sinus tract activity. Works through gut clearance, liver support, and lymphatic stimulation — addressing the three primary channels through which inflammatory metabolites accumulate and recirculate. In tunnel-forming HS, this phase typically requires longer sustained use than in earlier stages, as the burden is proportionally greater.
Immune Regulation Blend
By the tunnel-forming stage, the immune system is dysregulated — not merely overactive, but dysregulated in a way that sustains chronic inflammation while becoming progressively less effective at resolving it. This formulation is designed to modulate immune signalling — reducing the sustained inflammatory cascade in affected tissue while supporting normal immune function elsewhere. It is calibrated to the patient's specific immune pattern, not applied generically.
Blood Purification and Lymphatic Support Formula
Supports the clearance of inflammatory mediators from the blood and facilitates lymphatic drainage in regions where stagnation — from repeated inflammation and fibrosis — has compromised normal fluid movement. Improved lymphatic function is a prerequisite for meaningful local healing in tunnel-forming HS, where lymphatic architecture in affected areas is typically significantly disrupted.
Tissue Repair and Anti-Fibrotic Blend
A structurally targeted formulation that supports the remodelling of fibrotic tissue accumulated from years of repeated inflammation. Promotes new tissue formation with more organised collagen architecture, improves microvascular supply to healing areas, and reduces the chronic low-grade inflammation within sinus tract walls that prevents spontaneous improvement. This phase is slow but measurable — healing in fibrotic tissue occurs over months, not weeks.
Gut Restoration and Microbiome Support Formula
Gut dysfunction is both a primary driver and a consequence of long-standing HS. Years of antibiotic use — common in tunnel-forming HS patients — have typically significantly disrupted the gut microbiome, impaired the intestinal barrier, and altered the inflammatory signalling that the gut sends systemically. This formulation addresses restoration of gut function as an ongoing therapeutic target, not just a one-time clearance.
Topical Sinus Tract Support Application
A complementary external preparation applied to active sinus tract sites — reducing surface inflammation, supporting the reduction of discharge, and creating a local environment more conducive to tissue repair. Designed to work in conjunction with the internal formulations rather than as an independent treatment. The composition changes as the local tissue state evolves through treatment phases.
Formulations for tunnel-forming HS are more complex than earlier stages — reflecting the multi-system involvement and the depth of the structural and inflammatory changes present. The specific composition for each patient is determined through evaluation of their gut status, immune pattern, hormonal profile, disease stage, and treatment history. No herb names are listed here — the therapeutic function is what matters, and that function is achieved through compositions that vary significantly between patients with superficially similar presentations.
HS Presents at Different Stages and in Different Patterns
Tunnel-forming HS develops from earlier-stage presentations. Understanding how HS begins — and what drives its progression to this stage — is relevant for patients who want to understand their full disease history and what the treatment approach is addressing.
Sinus Tracts Are Not the End of the Road
Tunnel-forming HS is the most structurally established form of the condition — but structural establishment does not mean the disease is untreatable. The internal inflammatory process that created the tunnels can be corrected. When it is, the conditions that sustained active tunnel formation change. A structured evaluation identifies the specific drivers active in your case and forms the basis of a phased treatment plan designed for this stage.